Comparative Pharmacology
Head-to-head clinical analysis: APIDRA SOLOSTAR versus HUMALOG KWIKPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APIDRA SOLOSTAR versus HUMALOG KWIKPEN.
APIDRA SOLOSTAR vs HUMALOG KWIKPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin glulisine is a recombinant human insulin analog that lowers blood glucose by binding to insulin receptors on muscle and fat cells, facilitating glucose uptake, and inhibiting hepatic glucose production.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by binding to insulin receptors on skeletal muscle and adipose tissue, facilitating glucose uptake, and inhibiting hepatic glucose production.
Subcutaneous injection, 0.2-0.4 units/kg/day divided into two or more doses; for basal-bolus therapy, total daily dose is 0.5-1.0 units/kg/day with 50-60% as prandial insulin glulisine.
Subcutaneous injection: individualize dose; typical total daily dose 0.5-1 unit/kg; rapid-acting insulin given 0-15 minutes before or immediately after meals.
None Documented
None Documented
1.0-1.5 hours (terminal elimination half-life; consistent with rapid absorption and clearance; shorter than regular human insulin)
Terminal elimination half-life: approximately 26 minutes (range 0.6-1.2 hours in some studies) following subcutaneous administration, reflecting rapid clearance from the systemic circulation.
Renal: 60-80% of dose as metabolites and parent drug; biliary/fecal: minor (20-40%)
Renal: 60-80% of insulin lispro is metabolized primarily in the liver and kidneys, with metabolites and a small amount of intact drug excreted in urine.
Category C
Category C
Insulin
Insulin